TORL-5-700
Undisclosed Hematologic Malignancy
Phase 1Active
Key Facts
About TORL BioTherapeutics
TORL BioTherapeutics is a private, pre-revenue biotech advancing a pipeline of targeted antibody-drug conjugates for oncology, with its lead program, TORL-1-23, in Phase 2 development for CLDN6+ cancers. The company leverages a unique, scalable drug discovery engine born from a strategic partnership with the Slamon Research Lab at UCLA, enabling the identification of promising targets and patient selection biomarkers. Led by an experienced team with deep oncology drug development and commercialization expertise, including former Celgene CEO Mark Alles, TORL is positioned to advance its multi-asset pipeline through global clinical development.
View full company profile